Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hasane Ratni

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Pharmacology Research & Perspectives|December 7, 2018
Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organsAgnès Poirier, Marla Weetall, Katja Heinig, et al.
Human Molecular Genetics|January 14, 2016
Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onsetZhihua Feng, Karen K Y Ling, Xin Zhao, et al.
Human Molecular Genetics|November 17, 2020
Corrigendum to: Pharmacologically-induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onsetZhihua Feng, Karen K Y Ling, Xin Zhao, et al.
Frontiers in Pharmacology|June 15, 2026
Pharmacology of nivegacetor (RG6289), a potent and selective gamma secretase modulator in clinical development for the treatment of Alzheimer's diseaseLothar Lindemann, Julie Lambotte, Judith Rothe, et al.
British Journal of Clinical Pharmacology|October 11, 2018
A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifierStefan Sturm, Andreas Günther, Birgit Jaber, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Discovery of RO7185876, a Highly Potent γ-Secretase Modulator (GSM) as a Potential Treatment for Alzheimer's DiseaseHasane Ratni, Andre Alker, Bjoern Bartels, et al.
Journal of Medicinal Chemistry|January 18, 2020
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum DisorderPatrick Schnider, Caterina Bissantz, Andreas Bruns, et al.
Human Molecular Genetics|August 9, 2021
SMN protein is required throughout life to prevent spinal muscular atrophy disease progressionXin Zhao, Zhihua Feng, Nicole Risher, et al.
Human Molecular Genetics|March 3, 2016
Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophyXin Zhao, Zhihua Feng, Karen K Y Ling, et al.
Journal of Medicinal Chemistry|June 15, 2016
Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular AtrophyHasane Ratni, Gary M Karp, Marla Weetall, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Pharmacology Research & Perspectives|December 7, 2018
Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organsAgnès Poirier, Marla Weetall, Katja Heinig, et al.
Human Molecular Genetics|January 14, 2016
Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onsetZhihua Feng, Karen K Y Ling, Xin Zhao, et al.
Human Molecular Genetics|November 17, 2020
Corrigendum to: Pharmacologically-induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onsetZhihua Feng, Karen K Y Ling, Xin Zhao, et al.
Frontiers in Pharmacology|June 15, 2026
Pharmacology of nivegacetor (RG6289), a potent and selective gamma secretase modulator in clinical development for the treatment of Alzheimer's diseaseLothar Lindemann, Julie Lambotte, Judith Rothe, et al.
British Journal of Clinical Pharmacology|October 11, 2018
A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifierStefan Sturm, Andreas Günther, Birgit Jaber, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Discovery of RO7185876, a Highly Potent γ-Secretase Modulator (GSM) as a Potential Treatment for Alzheimer's DiseaseHasane Ratni, Andre Alker, Bjoern Bartels, et al.
Journal of Medicinal Chemistry|January 18, 2020
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum DisorderPatrick Schnider, Caterina Bissantz, Andreas Bruns, et al.
Human Molecular Genetics|August 9, 2021
SMN protein is required throughout life to prevent spinal muscular atrophy disease progressionXin Zhao, Zhihua Feng, Nicole Risher, et al.
Human Molecular Genetics|March 3, 2016
Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophyXin Zhao, Zhihua Feng, Karen K Y Ling, et al.
Journal of Medicinal Chemistry|June 15, 2016
Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular AtrophyHasane Ratni, Gary M Karp, Marla Weetall, et al.
Pageof 3